Background: The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be associated with tau pathology. In this combined positron emission tomography (PET) and magnetoencephalography (MEG) study, we aimed to investigate spatial associations between regional tau pathology ([18F]flortaucipir PET), synaptic density (synaptic vesicle 2A [11C]UCB-J PET) and synaptic function (MEG) in Alzheimer’s disease. Methods: Seven amyloid-positive Alzheimer’s disease subjects from the Amsterdam Dementia Cohort underwent dynamic 130-min [18F]flortaucipir PET, dynamic 60-min [11C]UCB-J PET with arterial sampling and 2 × 5-min resting-state MEG measurement. [18F]flortaucipir- and [11C]UCB-J-specific binding (binding potential, BPND) an...
Neuropathological and in vivo studies have revealed a tight relationship between tau pathology and c...
Importance: In Alzheimer disease (AD), tau filaments form neuronal inclusions in neurites (neuropil ...
Purpose: In vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF)...
Background: The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be as...
Background: The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be as...
Background: The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be as...
Understanding the role of Tau protein aggregation in the pathogenesis of Alzheimer's disease is crit...
Understanding the role of Tau protein aggregation in the pathogenesis of Alzheimer's disease is crit...
Tau pathology and neuroinflammation are key etio-pathogenetic mediators of Alzheimer’s disease (AD)....
Background: Neuropathological studies have linked tau aggregates to neuronal loss. To describe the s...
Background: Neuropathological studies have linked tau aggregates to neuronal loss. To describe the s...
Background: Neuropathological studies have linked tau aggregates to neuronal loss. To describe the s...
Background: Neuropathological studies have linked tau aggregates to neuronal loss. To describe the s...
OBJECTIVE: To investigate in vivo whether synaptic loss and neurofibrillary tangle load spatially ov...
OBJECTIVE: To investigate the topographical distribution of tau pathology and its effect on function...
Neuropathological and in vivo studies have revealed a tight relationship between tau pathology and c...
Importance: In Alzheimer disease (AD), tau filaments form neuronal inclusions in neurites (neuropil ...
Purpose: In vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF)...
Background: The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be as...
Background: The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be as...
Background: The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be as...
Understanding the role of Tau protein aggregation in the pathogenesis of Alzheimer's disease is crit...
Understanding the role of Tau protein aggregation in the pathogenesis of Alzheimer's disease is crit...
Tau pathology and neuroinflammation are key etio-pathogenetic mediators of Alzheimer’s disease (AD)....
Background: Neuropathological studies have linked tau aggregates to neuronal loss. To describe the s...
Background: Neuropathological studies have linked tau aggregates to neuronal loss. To describe the s...
Background: Neuropathological studies have linked tau aggregates to neuronal loss. To describe the s...
Background: Neuropathological studies have linked tau aggregates to neuronal loss. To describe the s...
OBJECTIVE: To investigate in vivo whether synaptic loss and neurofibrillary tangle load spatially ov...
OBJECTIVE: To investigate the topographical distribution of tau pathology and its effect on function...
Neuropathological and in vivo studies have revealed a tight relationship between tau pathology and c...
Importance: In Alzheimer disease (AD), tau filaments form neuronal inclusions in neurites (neuropil ...
Purpose: In vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF)...